Musculoskeletal Pain Market Poised for Transformation During the Forecast Period (2026-2036) as Novel Therapies and Non-Opioid Approaches Reshape Treatment | DelveInsight

The musculoskeletal pain treatment market is projected to grow steadily through 2036, supported by a global patient pool of ~1.7 billion people affected and rising demand for non-opioid and minimally invasive care. The outlook is increasingly driven by emerging potential disease-modifying therapies, including Mesoblast’s rexlemestrocel-L (FDA BLA feedback for chronic discogenic CLBP), Taiwan Liposome’s TLC599 (exploratory Phase III data at OARSI 2026 suggesting reduced joint structural deterioration), and Biosplice’s Lorecivivint (NDA submitted to the FDA for knee osteoarthritis). Overall, the article frames a gradual positive shift from symptomatic treatments (e.g., NSAIDs and injections) toward longer-lasting/regenerative options, but provides no direct pricing or near-term stock/sector numbers.

Analysis

This is more of a TAM-validation signal than a near-term revenue event. The investable angle is that if one regenerative/disease-modifying therapy gets credible clinical and regulatory traction, the market stops pricing the space as a commoditized injection business and starts assigning option value to procedure replacement, which is where the multiple expansion lives.

MESO is the clearest asymmetrical beneficiary because durable functional benefit would move it from a niche pain asset to a potential pathway to deferral of repeat steroid/viscosupplement use and, in a subset, surgery. The flip side is that payers will not pay for narrative; they will pay for fewer procedures, better function, and lower downstream utilization, so any benefit that does not translate into hard economics will cap adoption quickly. PCRX is the main incumbent exposed to that shift, but only if investors begin to believe the new category is real rather than promotional.

The contrarian view is that the market is likely overestimating how fast specialist pain workflows change. Even with positive data, uptake is usually gated by coding, prior auth, and physician habit, so the first 1-3 months after catalysts can be driven by sentiment while 6-18 months determine whether this is a durable category or another small-commercialization disappointment. Falsifiers for the bullish MESO read are weak durability, ambiguous functional endpoints, FDA friction, or pricing that lands below the economics of repeat injections.

Key Decisions for Investors

• Do not trade the report alone; treat it as a watchlist item and wait for MESO-specific regulatory acceptance or label language before adding risk. Time horizon: days = noise, 1-3 months = actionable catalyst.
• On any pre-catalyst pullback, consider a tactical long MESO vs short XBI pair to isolate idiosyncratic upside from broader biotech beta. Risk/reward is best only if FDA path remains intact; exit if the company loses regulatory momentum.
• Use PCRX as the incumbent hedge: if the market starts to price regenerative therapies as real, short PCRX against MESO on strength. This works only if investors begin rotating out of repeat-procedure assets into longer-duration alternatives.
• Set an alert for payer/access language around MESO and similar OA/CLBP assets; if reimbursement assumptions weaken, the 'disease-modifying' premium can unwind faster than clinical enthusiasm. Falsifier: lack of evidence that the therapy reduces downstream procedures or improves function enough to change coverage decisions.